We're committed to rigorous and ongoing evaluation.
Browse our latest publications below.
Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design
Research Presented at ACTRIMS 2024 - February 29 - March 1
Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan
Research Presented at MSMilan 2023 - October 11-13
CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis
Research Presented at MSMilan 2023 - October 11-13
Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population
Research Presented at MSMilan 2023 - October 11-13
Interpretable Thalamic Volume Charts in Multiple Sclerosis
Research Presented at MSMilan 2023 - October 11-13
Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies
Research Presented at MSMilan 2023 - October 11-13
Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design
Research Presented at ACTRIMS 2024 - February 29 - March 1
Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan
Research Presented at MSMilan 2023 - October 11-13
CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis
Research Presented at MSMilan 2023 - October 11-13
Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population
Research Presented at MSMilan 2023 - October 11-13
Interpretable Thalamic Volume Charts in Multiple Sclerosis
Research Presented at MSMilan 2023 - October 11-13
Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies
Research Presented at MSMilan 2023 - October 11-13